In a recent transaction, Andrew M. Green, the Vice President of Regulatory at Artivion, Inc. (NYSE:AORT), sold 3,994 shares of the company's common stock. The sale, which took place on March 14, 2024, was executed at a price of $20.00 per share, resulting in a total transaction value of $79,880.
The sale was conducted under a pre-arranged 10b5-1 trading plan, which Mr. Green had adopted on December 14, 2023. This type of trading plan allows corporate insiders to sell shares over a determined period of time, providing an affirmative defense against accusations of trading on non-public information.
Following the transaction, Andrew M. Green's holdings in Artivion have decreased, yet he still owns a substantial number of shares in the company, with 42,583 shares remaining in his possession.
Investors often monitor insider transactions as they can provide insights into an insider's perspective on the company's performance and future prospects. However, these transactions may not always be indicative of a company's trajectory and should be considered alongside other factors.
Artivion, Inc., headquartered in Kennesaw, Georgia, operates in the medical devices sector, specializing in surgical and medical instruments and apparatus. The company, formerly known as CryoLife Inc., is incorporated in Delaware and continues to be a key player in its industry.
InvestingPro Insights
Artivion, Inc. (NYSE:AORT) has been under the investor's microscope recently, especially following insider trading activity. As the Vice President of Regulatory, Andrew M. Green's sale of company shares has piqued market interest. To further understand the financial health and potential of Artivion, let’s delve into some key metrics from InvestingPro and glean insights from InvestingPro Tips.
InvestingPro data shows a market capitalization of $809.25 million, reflecting the company's size and market value. Despite a negative P/E ratio of -26.39, analysts have a positive outlook, as indicated by a PEG ratio of 0.48, suggesting that the company's earnings are expected to grow. In terms of performance, Artivion has experienced a revenue growth of 12.82% over the last twelve months as of Q4 2023, with a notable quarterly increase of 17.98% in Q4 2023.
From the InvestingPro Tips, it's noteworthy that Artivion has raised its dividend for 4 consecutive years and is expected to see net income growth this year. However, it's crucial to be aware of the company's volatility, as stock price movements have been quite volatile. Additionally, while Artivion has not been profitable over the last twelve months, analysts predict the company will be profitable this year. This aligns with the substantial price uptick of 35.56% over the last six months and a year-to-date price total return of 12.36%, indicating strong recent performance.
For investors seeking a more in-depth analysis, there are additional InvestingPro Tips available for Artivion, which can be accessed at https://www.investing.com/pro/AORT. These tips could provide valuable insights for making informed investment decisions. Remember to use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking even more data and insights for your investment strategy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.